Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Niskanen J
Br J Clin Pharmacol. 1982;13(Suppl 2):445S-447S. doi: 10.1111/j.1365-2125.1982.tb01955.x.
1 The effect on plasma lipids of pindolol given orally over a 6 month period to 20 patients with essential hypertension was studied. 2 During therapy an adipose tissue biopsy was taken from nine patients for the determination of lipoprotein lipase (LPL) activity and serum samples were taken for lecithin cholesterol acyltransferase (LCAT) assays. An additional biopsy and serum samples were taken after a 3 weeks' break in pindolol treatment. 3 Plasma free fatty acid and triglyceride concentrations remained similar during treatment. 4 Plasma total cholesterol was slightly lower (P less than 0.05) at 6 months than at 1 month. 5 HDL cholesterol concentration and the ratio of HDL to total cholesterol increased slightly, and the increase of HDL-cholesterol was significant (P less than 0.05) at 1 month. 6 LCAT activity was significantly higher (P less than 0.01) during pindolol treatment than after the break in it. No significant changes in adipose tissue LPL activities were found before and after the break of treatment.
1 研究了对20例原发性高血压患者口服吲哚洛尔6个月对血脂的影响。2 在治疗期间，对9例患者进行了脂肪组织活检以测定脂蛋白脂肪酶（LPL）活性，并采集血清样本进行卵磷脂胆固醇酰基转移酶（LCAT）测定。在吲哚洛尔治疗中断3周后，又进行了一次活检并采集了血清样本。3 治疗期间血浆游离脂肪酸和甘油三酯浓度保持相似。4 6个月时血浆总胆固醇略低于1个月时（P<0.05）。5 HDL胆固醇浓度以及HDL与总胆固醇的比值略有增加，且1个月时HDL胆固醇的增加具有显著性（P<0.05）。6 吲哚洛尔治疗期间LCAT活性显著高于治疗中断后（P<0.01）。治疗中断前后脂肪组织LPL活性未发现显著变化。
